Navigation Links
JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
Date:1/30/2008

danani of the Mayo clinic said: "In ex vivo studies, we have seen encouraging preliminary results with Cytopia's compounds including the inhibition of erythroid colony growth from PV patients harboring the JAK2 V617F mutation."

Cytopia's Research Director Dr Chris Burns stated: "This data is important validation that our selective JAK2 inhibitors stop the proliferation of mutant cells from patients with these diseases at clinically achievable doses."

Cytopia is developing JAK2 inhibitors for the treatment of MPDs and other solid and blood cancers. In addition, other inhibitors of JAK2 are under development for cardiovascular and ophthalmic diseases.

About Cytopia

Cytopia Ltd is an Australian headquartered biotechnology company focused on the discovery and development of new drugs to treat cancer. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

http://www.cytopia.com.au

Relevant Links:

http://www.mpdfoundation.org

http://www.mpd-oz.org


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
4. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
5. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
8. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
9. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
10. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
11. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... measurement solutions for cardiovascular applications, today announced that they have ... Philips will commence a tender offer to acquire all of ... per share, or a total equity purchase price of USD ...
(Date:12/17/2014)... NASHVILLE, Tenn. , Dec. 17, 2014  Strategic ... health management software solutions, today announced a strategic agreement ... the New Jersey regional marketplace.  ... and enhance the health and wellness solutions QualCare brings ... and the surrounding region. QualCare ...
(Date:12/17/2014)... SCOTTSDALE, Ariz. , Dec. 17, 2014 /PRNewswire/ ... of state-of-the-art interactive music products, today announced that ... Ltd, a leading manufacturer and supplier of innovative ... As part of the agreement, RSL ... Facility bundled solution specifically configured for use within ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3
... LITTLE FALLS, N.J., Nov. 5 CANTEL MEDICAL CORP. ... Krakauer, President & CEO, will be presenting at the Sidoti ... formal presentation is scheduled for 9:05 AM ET on Friday, ... a Q & A session immediately following the presentation. In ...
... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced ... voreloxin orphan drug designation for the treatment of acute ... 2 clinical trials of voreloxin in AML: a single-agent ... elderly AML patients unlikely to benefit from standard induction ...
Cached Medicine Technology:Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3
(Date:12/21/2014)... Coral Gables, FL (PRWEB) December 21, 2014 ... of head lice, who do they call? The new answer ... Leon Blvd, Coral Gables FL 33134, their newest treatment center ... eradicate this pest quickly, conveniently and without the use of ... Grand Opening is scheduled for January 1, 2015. Like the ...
(Date:12/21/2014)... By Dennis Thompson ... -- Former tobacco smokers find e-cigarettes less addictive than traditional ... e-cigarettes as often as they did regular cigarettes, thousands of ... to feel impulsive and irritable over their need to smoke, ... clear. The score was significantly less for e-cig use than ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading Christmas ... time helping people get their health back. Mission for ... serving those persons in Muskegon County who are unable to ... of life. Dr. Michael Rykse wanted to do a Toy ... and he knew he found that when he heard what ...
(Date:12/21/2014)... Tiburon, CA (PRWEB) December 21, 2014 ... and resolved performance issues in hundreds of emergency departments ... patient satisfaction. Its findings have been translated into an ... hospital leaders to correct deficiencies and enhance the patient ... of outsourced emergency physician staffing and management services for ...
(Date:12/21/2014)... As testosterone therapy lawsuit filings on ... clots from using testosterone products such as AndroGel and ... the male hormone testosterone may increase the risk of ... the Proceedings of the National Academy of Sciences in ... male rats with naturally occurring colon cancer. Dr. Amos-Landgraf, ...
Breaking Medicine News(10 mins):Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4
... HealthDay Reporter , WEDNESDAY, Oct. 27 (HealthDay ... the vaccine that protects against bacterial meningitis, a U.S. ... the recommendation because the vaccine appears not to last ... U.S. Centers for Disease Control and Prevention,s Advisory Committee ...
... develops and spreads much more slowly than scientists have ... The finding indicates that there is a potentially broad ... "For the first time, we have a quantifiable estimate ... would be best to intervene," according to Christine Iacobuzio-Donahue, ...
... planning of care and stronger relationships with physicians are ... a study by a Queen,s University professor. , "High ... Canadian," says professor of Medicine and Epidemiology Daren Heyland, ... "But it,s not always happening. We know from international ...
... , WEDNESDAY, Oct. 27 (HealthDay News) -- With October ... offers breast cancer survivors some guidance on what they ... Karen Syrjala, director of biobehavioral sciences and co-director of ... Center in Seattle, touches upon both the lingering physical ...
... Carolina (UNC) researchers report in the November issue of ... diagnostic testing are overused in treating chronic neck pain. ... for neck pain, such as therapeutic exercise. According to ... effectiveness of therapeutic exercise in treating chronic neck pain ...
... not considered effective treatment for KRAS (a gene)-mutated metastatic ... cancer not responding to chemotherapy and a certain variation ... longer overall and progression-free survival than patients with other ... issue of JAMA . "Recent retrospective ...
Cached Medicine News:Health News:Teens Should Get Meningitis Booster Shot: CDC Panel 2Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 2Health News:Surprise finding: Pancreatic cancers progress to lethal stage slowly 3Health News:Women Urged to Reclaim Their Life After Breast Cancer 2Health News:Narcotics and diagnostics overused in treatment of chronic neck pain 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: